Ayrton Drug Manufacturing
- • Last trade was 37 days ago. Latest price is not fresh.
- Day range
- GH₵0.11 – GH₵0.12
- Volume
- 15,000
- Market cap
- GH₵28M
- Shares out.
- 255M
- Dividend / share
- —
- Yield (trailing)
- —
- P/E
- —
- Real 1y (USD)
- -29.35%
What Nkosuo is seeing
What happened
AYRTN did not trade today — last print was 37 days ago at 0.11 GHS.
Liquidity
AYRTN trades thinly. Orders can move the price disproportionately; limit orders are strongly advised. Liquidity grade E.
Supply and demand
The close sat near the day low; sellers had the upper hand for the session.
Narrative
No direct headline mentions of Ayrton Drug Manufacturing in the last refresh.
Dividend
No trailing dividend on file for AYRTN. Check the issuer's next AGM notice for guidance.
Automatically generated from public market data and the Ghanaian news feed. Descriptive only. Not investment advice, not a prediction, not a recommendation.
Why the stock moved
AYRTN closed roughly flat slightly today, closing at GHS 0.11.
Cited data inputs
- Previous close
- GHS 0.11
- Day range
- GHS 0.11 – GHS 0.12
- Volume
- 15,000
- Last traded
- 2026-04-10
Limitations
- • End-of-day data only; we do not have intraday prints.
- • This explanation is descriptive, not predictive.
Descriptive only. Not investment advice. No buy / sell / hold output. AI disclaimer →
About
Ayrton Drug Manufacturing Ltd, pharmaceutical producer.
Curated by Nkosuo's editorial team. Not investment advice.
Fundamentals snapshot
Six categories: identity & capital · multiples · earnings & growth · profitability · trading · returns. Scroll horizontally on narrow screens.
Identity & capital
- SectorHealthcare
- Industry—
- Listed2010-08-10
- Market CapGHS 28.00M
- Enterprise Value—
- Sales (TTM)—
- Net income (TTM)—
- EBITDA (TTM)—
- FCF (TTM)—
- Book / share—
- Cash / share—
- Total debt—
- Cash—
- Auditor—
Multiples
- P/E—
- Forward P/E—
- PEG—
- P/B—
- P/S—
- P/C—
- P/FCF—
- EV/EBITDA—
- EV/Sales—
- Debt / Equity—
- Current Ratio—
- Quick Ratio—
- Dividend Cover—
- Beta—
Earnings & growth
- EPS (TTM)—
- EPS forward—
- EPS growth (5Y)—
- Sales growth (5Y)—
- EPS Y/Y—
- Sales Y/Y—
- Dividend / share—
- Dividend yield—
- Payout ratio—
- Div growth (3Y)—
- Div growth (5Y)—
- Last dividend—
- Last earnings—
- EPS / Sales surprise—
Profitability
- ROE—
- ROA—
- ROIC—
- Gross margin—
- Net margin—
- Operating margin—
- vs SMA20+29.23%
- vs SMA50+29.26%
- vs SMA200—
- RSI (14)52.1
- Volatility (30d ann.)+27.8%
- Insider %—
- Institutional %—
- Short interest—
Trading
- Shares outstanding255.00M
- Volume (last)15.00K
- Avg volume15.00K
- Day low0.11
- Day high0.12
- 52W high0.11
- 52W low0.08
- % from 52W high-20.99%
- % from 52W low+7.08%
- Last traded2026-04-10
- Previous close0.11
- Price0.11
- Day change0.00%
- Float—
Returns
- 1 day+1.77%
- 1 week-1.49%
- 1 month+2.01%
- 3 month-4.96%
- 6 month—
- YTD-15.90%
- 1 year—
- 3 year—
- 5 year—
- 10 year—
- 1Y real (CPI-adj.)—
- 1Y FX-adj. (USD)—
- Analyst target—
- Recommendation—
Fundamentals & ratios
Trailing twelve-month figures unless otherwise stated.
Fundamentals not yet tracked for this issuer.
Educational only, not investment advice. How read?
Educational valuation scenarios
Four independent models. Assumption-sensitive ranges — not recommendations, not price targets.
Educational models. Intrinsic value is an estimate, not a forecast. Ghana-aware discount rates (20–24%) reflect local sovereign yields. Nothing on this card is a recommendation to buy or sell.
Valuation toolkit
Interactive dividend-discount and two-stage DCF calculators. Inputs are seeded from public fundamentals and Ghana-specific defaults — change them to see how the implied fair value moves. Educational only. Not a fair-value target, not investment advice.
Dividend Discount Model (Gordon)
Fair value = DPS × (1 + g) / (r − g)
- ⚠ DDM requires a positive current dividend per share.
Two-stage DCF
5 years of explicit growth + Gordon-growth terminal value, discounted to today.
- ⚠ DCF requires positive free cash flow.
Outputs are educational estimates subject to input assumptions. Not a fair-value target, not investment advice. How calculated?
Peer multiples
P/E, P/B, and trailing dividend yield for AYRTN against sector peers. Medians shown for reference.
| Ticker | P/E | P/B | Div yield |
|---|---|---|---|
| AYRTNthis stock | — | — | — |
| HORDS | — | — | — |
| IIL | — | — | — |
| DASPHARMA | — | — | — |
| Median | — | — | — |
“Discount” / “premium” describes this stock's multiple relative to the peer median only — a cheap multiple can be justified by weaker fundamentals. Educational only.
AYRTN dividend yield vs T-Bills
Informational comparison. T-Bills are near-risk-free; dividend yield carries principal risk. Not investment advice.
- 364-day T-Bill37.87%
- 91-day T-Bill26.44%
- Stock dividend yield0.00%
- Ghana headline CPI17.80%
- Real stock yield
- -17.80%
- Real 91-day T-Bill
- 8.64%
- Real 364-day T-Bill
- 20.07%
Real yields subtract Ghana's current CPI. A negative real yield means your purchasing power is eroding, nominal income notwithstanding.
Sector peers
Auto-selected from Healthcare by market-cap proximity
Price & indicators
End-of-day data. Technical indicators are descriptive tools — they do not predict future prices and are not recommendations. Drawing tools available on globally-listed names via the TradingView panel below.
Recent mentions of AYRTN
No direct company news found from tracked sources
We didn't find any direct-company headlines for AYRTN in the last pull. See the full news feed for macro and market-wide stories.
Matched via whole-word ticker, company-name, alias, and former-name matching. Short tickers are never matched inside unrelated words. Low-confidence or macro/market-wide items are not shown on company pages.
Announcements & corporate actions
Source: GSE · Issuer filingsNo recent announcements on file.